CryoPort (NASDAQ:CYRX) Azioni

CRYOPORT INC

CryoPort

CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.

CryoPort Inc

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) lowers FY2025 sales outlook from $240.00 million-$250.00 million to $165.00 million-$172.00 million vs $186.04 million estimate.

News

Guidance

CYRX

CryoPort Lowers FY2025 Sales Guidance from $240.00M-$250.00M to $165.00M-$172.00M vs $186.04M Est

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.34) by 17.65 percent. This is a 34.88 percent increase over losses of $(0.43) per share from the same period last year. The company reported quarterly sales of $41.04 million which missed the analyst consensus estimate of $44.69 million by 8.17 percent. This is a 24.82 percent decrease over sales of $54.59 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

CryoPort Q1 EPS $(0.28) Beats $(0.34) Estimate, Sales $41.04M Miss $44.69M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

Earnings Scheduled For May 7, 2025

Across the recent three months, 10 analysts have shared their insights on CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $10.8, a high estimate of $15.00, and a low estimate of $7.00. Highlighting a 0.83% decrease, the current average has fallen from the previous average price target of $10.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1746471692_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive CryoPort. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Richard Baldry</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CryoPort. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CryoPort compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of CryoPort's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CryoPort's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CryoPort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About CryoPort</h2>
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
<h3>Understanding the Numbers: CryoPort's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: CryoPort's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 3.97%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -34.73%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): CryoPort's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.49%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CryoPort's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.94%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: CryoPort's debt-to-equity ratio is below the industry average at 0.68, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Forecasting The Future: 10 Analyst Projections For CryoPort

Morgan Stanley analyst Tejas Savant maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Equal-Weight and lowers the price target from $8 to $7.

Price Target

Morgan Stanley Maintains Equal-Weight on CryoPort, Lowers Price Target to $7

In the latest quarter, 10 analysts provided ratings for CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $11.2, a high estimate of $15.00, and a low estimate of $10.00. A 0.18% drop is evident in the current average compared to the previous average price target of $11.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1744830038_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of CryoPort by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Saxon &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $11.00&#x7C;$11.00 &#x7C; 
&#x7C;Subbu Nambi &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $10.00&#x7C;$10.00 &#x7C; 
&#x7C;David Saxon &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $11.00&#x7C;$11.00 &#x7C; 
&#x7C;Richard Baldry &#x7C;Roth MKM &#x7C;Maintains &#x7C;Buy &#x7C; $15.00&#x7C;$15.00 &#x7C; 
&#x7C;John Sourbeer &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $11.00&#x7C;$10.00 &#x7C; 
&#x7C;David Saxon &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $11.00&#x7C;$11.00 &#x7C; 
&#x7C;David Saxon &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $11.00&#x7C;$11.00 &#x7C; 
&#x7C;John Sourbeer &#x7C;UBS &#x7C;Announces &#x7C;Buy &#x7C; $10.00&#x7C;- &#x7C; 
&#x7C;David Saxon &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $11.00&#x7C;$11.00 &#x7C; 
&#x7C;David Saxon &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $11.00&#x7C;$11.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CryoPort. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CryoPort compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of CryoPort's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CryoPort's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CryoPort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind CryoPort</h2>
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
<h3>CryoPort's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: CryoPort's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 3.97%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CryoPort's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -34.73%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CryoPort's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.49% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): CryoPort's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.94%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: CryoPort's debt-to-equity ratio is below the industry average. With a ratio of 0.68, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Have This To Say About CryoPort

Needham analyst David Saxon reiterates CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and maintains $11 price target.

Reiteration

Needham Reiterates Buy on CryoPort, Maintains $11 Price Target

Guggenheim analyst Subbu Nambi reiterates CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and maintains $10 price target.

Guggenheim Reiterates Buy on CryoPort, Maintains $10 Price Target

Roth MKM analyst Richard Baldry reiterates CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and maintains $15 price target.

Roth MKM Reiterates Buy on CryoPort, Maintains $15 Price Target

UBS analyst John Sourbeer maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and raises the price target from $10 to $11.

UBS Maintains Buy on CryoPort, Raises Price Target to $11

Analysts' ratings for CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for CryoPort, presenting an average target of $10.75, a high estimate of $11.00, and a low estimate of $10.00. Highlighting a 2.27% decrease, the current average has fallen from the previous average price target of $11.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1743458458_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of CryoPort's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CryoPort. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CryoPort compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of CryoPort's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CryoPort's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CryoPort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind CryoPort</h2>
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
<h3>CryoPort: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: CryoPort's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 3.97%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CryoPort's net margin is impressive, surpassing industry averages. With a net margin of -34.73%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CryoPort's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.49%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CryoPort's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.94%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: CryoPort's debt-to-equity ratio is below the industry average. With a ratio of 0.68, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: CryoPort Through The Eyes Of 4 Analysts

U.S. stocks were mixed, with the Nasdaq Composite falling over 1% on Monday.
Shares of Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) rose sharply during Monday's session after the company announced it will be acquired by Rocket Companies in a $9.4 billion <a href="https://www.benzinga.com/quote/COOP">all-stock deal</a>.
Mr. Cooper Group shares jumped 16.3% to $ 121.54 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) shares jumped 84.7% to $100.95 after the company announced it met its primary endpoint for its Phase 3 ROSELLA trial of Relacorilant.</li>
<li>United Microelectronics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMC#NYSE">UMC</a>) shares rose 12.6% to $7.38.</li>
<li>Gorilla Technology Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) gained 12.6% to $28.20.</li>
<li>Southern States Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSBK#NASDAQ">SSBK</a>) rose 10.2% to $35.79 after FB Financial announced it will acquire the company in a $381 million merger deal.</li>
<li>B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) jumped 9.6% to $7.05.</li>
<li>Park Ha Biological Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHH#NASDAQ">PHH</a>) gained 9.5% to $14.00.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) gained 8.8% to $6.63 after DHL Group announced it will acquire its CRYOPDP business for $138 million.</li>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) rose 8.2% to $36.42.</li>
<li>Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) gained 7.6% to $8.20.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) rose 6.8% to $1.9550.</li>
<li>Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) shares gained 5.4% to $167.34. Discover Financial Services will report its first quarter 2025 results after the market closes on Wednesday, April 23.</li>
<li>The Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) gained 4% to $9.14. Deutsche Bank analyst Edison Yu upgraded Goodyear Tire &amp; Rubber from Hold to Buy and announced a $13 price target.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44554966/pvh-progress-software-and-3-stocks-to-watch-heading-into-monday">PVH, Progress Software And 3 Stocks To Watch Heading Into Monday</a></li>
</ul>
Photo: Shutterstock

Intraday Update

Markets

Movers

Trading Ideas

CELH

COOP

CORT

GRRR

NEXN

NVTS

SSBK

Mr. Cooper Group, Southern States Bancshares, Corcept Therapeutics And Other Big Stocks Moving Higher On Monday

WIIM

CrypPort shares are trading higher after DHL Group announced it will acquire its CRYOPDP business for $138 million.

<ul>
<li>DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell &amp; gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics.</li>
<li>DHL and Cryoport form strategic partnership to strengthen their respective supply chain services offerings for the global life sciences and healthcare sector.</li>
</ul>

Asset Sales

DHL Group Acquires Cryoport's CRYOPDP; Terms Not Disclosed

<h3>Gainers</h3>
<ul>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) shares moved upwards by 75.6% to $3.02 during Monday's regular session. The market value of their outstanding shares is at $4.2 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock rose 57.28% to $2.38. The company's market cap stands at $14.1 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock rose 26.24% to $29.07. The company's market cap stands at $187.0 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) shares moved upwards by 23.57% to $3.35. The company's market cap stands at $110.7 million. As per the news, the Q4 earnings report came out today. </li>
<li>CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) stock rose 23.55% to $7.03. The market value of their outstanding shares is at $350.8 million. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) stock moved upwards by 22.81% to $1.22. The market value of their outstanding shares is at $92.4 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) shares declined by 52.1% to $0.86 during Monday's regular session. The company's market cap stands at $23.0 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock fell 40.18% to $0.67. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares declined by 31.08% to $3.42. The company's market cap stands at $39.3 million. </li>
<li>Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) shares declined by 30.96% to $1.26. The company's market cap stands at $21.2 million. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) stock declined by 25.81% to $7.14. The market value of their outstanding shares is at $7.3 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock decreased by 24.64% to $10.77. The company's market cap stands at $93.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

CAPS

CRVO

KDLY

LXEO

RNAZ

TNXP

12 Health Care Stocks Moving In Monday's Intraday Session

CryoPort shares are trading higher after UBS upgraded the stock from Neutral to Buy and announced a price target of $10.

UBS analyst John Sourbeer upgrades CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) from Neutral to Buy and announces $10 price target.

Upgrades

UBS Upgrades CryoPort to Buy, Announces $10 Price Target

Small Cap

Press Releases

Cryoport's MVE Biological Solutions Registers All Manufacturing Facilities with the U.S. Food and Drug Administration ("FDA")

Moffitt Cancer Center and Cryoport Announce Strategic Collaboration

Cryoport Unveils State-of-the-Art Cryogenic Shipping System for Transporting Lifesaving Biologics and Temperature-Sensitive Therapies

Cryoport to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results

Contracts

Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series With Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories

Cryoport to Host Investor Call to Discuss Recent Strategic Agreement and Transformative Transaction Today, March 31, 2025, at 8:30 a.m. ET

Comments

CryoPort

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO